ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the founder and chairman of ImmunueOnco, Dr. Tian, Wenzhi, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024 and deliver a speech at the Biotech Showcase™ held at the same time, comprehensively demonstrate ImmuneOnco’s innovative product pipeline and progress in clinical research and development.

On October 27, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that 2 drug candidates independently developed by the company, IMM2510, a bispecific antibody-receptor recombinant protein targeting PD-L1/VEGFA and IMM27M, an ADCC-enhanced CTLA-4 monoclonal antibody, are proposed to combined for the treatment of advanced solid tumors.

On October 16, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the company's independently developed humanized IgG1 CD24 antibody(Project number: IMM47) was approved by the National Medical Products Administration (NMPA) for clinical trials.

On October 4, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that total 3 innovative clinical Phase II data of Timdarpacept (IMM01), the first SIRPαFc fusion protein targeting human CD47 in China, will be reported at the 2023 American Society of Hematology (ASH) Annual Meeting. Two phase II clinical data summary, for first-line MDS therapy and for cHL indications after PD1 antibody treatment failure will be presented orally, research results of first-line for CMML indication were presented in form of poster.

On September 27, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the newly developed humanized IgG1 CD24 antibody, IMM47, successfully completed the first subject enrollment and dosing in the Australian phase I clinical trial. This is another milestone achievement in the company's rapid development.